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The roles of 2-oxoglutarate (2OG)-dependent prolyl-hydroxylases
in eukaryotes include collagen stabilization, hypoxia sensing, and
translational regulation. The hypoxia-inducible factor (HIF) sensing
system is conserved in animals, but not in other organisms. How-
ever, bioinformatics imply that 2OG-dependent prolyl-hydroxy-
lases (PHDs) homologous to those acting as sensing components
for the HIF system in animals occur in prokaryotes. We report
cellular, biochemical, and crystallographic analyses revealing
that Pseudomonas prolyl-hydroxylase domain containing protein
(PPHD) contain a 2OG oxygenase related in structure and function
to the animal PHDs. A Pseudomonas aeruginosa PPHD knockout
mutant displays impaired growth in the presence of iron chelators
and increased production of the virulence factor pyocyanin. We
identify elongation factor Tu (EF-Tu) as a PPHD substrate, which
undergoes prolyl-4-hydroxylation on its switch I loop. A crystal
structure of PPHD reveals striking similarity to human PHD2 and
a Chlamydomonas reinhardtii prolyl-4-hydroxylase. A crystal struc-
ture of PPHD complexed with intact EF-Tu reveals that major con-
formational changes occur in both PPHD and EF-Tu, including
a >20-Å movement of the EF-Tu switch I loop. Comparison of
the PPHD structures with those of HIF and collagen PHDs reveals
conservation in substrate recognition despite diverse biological
roles and origins. The observed changes will be useful in designing
new types of 2OG oxygenase inhibitors based on various confor-
mational states, rather than active site iron chelators, which make
up most reported 2OG oxygenase inhibitors. Structurally in-
formed phylogenetic analyses suggest that the role of prolyl-
hydroxylation in human hypoxia sensing has ancient origins.
The hypoxia-inducible transcription factor (HIF) is a majorregulator of the response to limited oxygen availability in
humans and other animals (1–3). A hypoxia-sensing component of
the HIF system is provided by 2-oxoglutarate (2OG)-dependent
and Fe(II)-dependent oxygenases, which catalyze prolyl-4-hydrox-
ylation of HIF-α subunits, a posttranslational modification that
enhances binding of HIF-α to the von Hippel-Lindau protein
(pVHL), so targeting HIF-α for proteasomal degradation. The
HIF prolyl-hydroxylases (PHDs) belong to a subfamily of 2OG
oxygenases that catalyze prolyl-hydroxylation, which also includes
the collagen prolyl-3-hydroxylases (CP3Hs) and prolyl-4-hydrox-
ylases (CP4Hs) (4). Subsequently identified prolyl-hydroxylases
include the ribosomal prolyl-hydroxylases (OGFOD1 and Tpa1),
which catalyze ribosomal protein 23 prolyl-3-hydroxylation in many
eukaryotes, and slime-mold enzymes, which catalyze prolyl-4-hy-
droxylation of Skp1, a ubiquitin ligase subunit (5–9). The HIF-
PHD-VHL triad is likely present in all animals, but probably
not in other organisms (3). However, structurally informed
bioinformatic analyses imply the presence of PHD homologs in
bacteria (10, 11), including in Pseudomonas spp, suggesting
PHDs may have ancient origins.
Results
Pseudomonas spp. Contain a Functional PHD. To investigate the role
of a putative PHD homolog in Pseudomonas aeruginosa (PPHD),
we initially characterized a PPHD insertional mutant strain.
Metabolic screening studies revealed that the PPHDmutant strain
displays impaired growth in the presence of iron chelators (e.g.,
2,2-bipyridine) and produces increased levels of the bacterial vir-
ulence factor pyocyanin (SI Appendix, Fig. S1) (12), implying
PPHD is involved in iron regulation. Ferrous iron is essential for
PHD catalysis and treatment of human cells with iron chelators,
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including pyocyanin (13), and causes HIF-α up-regulation via
PHD inhibition, suggesting related roles for PPHD and the animal
PHDs (1).
Elongation Factor Tu Is a PPHD Substrate. We then investigated
possible PPHD substrates. Mass spectrometric (MS) studies
identified elongation factor Tu (EF-Tu) as a PPHD binding
partner and potential substrate in Pseudomonas putida (SI Ap-
pendix, Table S3). This assignment is supported by a proteomic
MS study on Shewanella oneidensis, reporting that EF-Tu is mod-
ified by a +16-Da mass shift (14); bioinformatics reveal Shewanella
oneidensis contains a potential hydroxylase closely related to
PPHD (38% identity). We tested a set of 14 synthetic peptides
covering the 19 prolines in the EF-Tu sequence as substrates for
isolated recombinant PPHDputida (SI Appendix, Table S4). We
identified an EF-Tu peptide as undergoing a +16-Da mass shift
(Fig. 1B and SI Appendix, Table S4); MSMS analyses demon-
strated hydroxylation at Pro54 (Hyp54; SI Appendix, Fig. S2A).
Amino acid analyses reveal that PPHDputida catalyzes trans
prolyl-4-hydroxylation of EF-Tu, as occurs for PHD-catalyzed
HIF and CP4H-catalyzed collagen prolyl-hydroxylation (SI Ap-
pendix, Fig. S2B) (1). We did not observe cross hydroxylation
reactivity between the PPHD and PHD2 substrates; that is, EF-
Tu with PHD2 and the C-terminal oxygen degradation domain
(CODD) of HIF-1α (CODD556–574) with PPHD.
EF-Tu undergoes hydroxylation in the wild-type but not in the
PPHD insertional mutant strain, as shown by MS studies (SI
Appendix, Fig. S3A and B). Because the human elongation factor
2 (eEF2) interacts with PHD2 (15), we tested peptides derived
from the switch I loop of human eEF2 as potential PPHD or
PHD2 substrates but did not observe hydroxylation within the
limits of detection.
Effect of Prolyl-Hydroxylation on EF-Tu Function. Kinetic analyses
were then carried out using a 20-residue EF-Tu fragment
(EF-Tu44–63). Compared with an analogous substrate fragment
with PHD2, PPHDputida has a similar apparent Km (47.2 ± 8.5
μM for PPHD/EF-Tu44–63; 36.7 ± 9.0 μM for PHD2/HIF-1α
CODD), but a lower apparent Km for O2 (47.5 ± 9.2 μM for
PPHD/EF-Tu44–63; 229 ± 60 μM for PHD2/HIF-1α CODD), and
higher apparent Km values for 2OG (182 ± 22 μM for PPHD/EF-
Tu44–63; 55 ± 11 μM for PHD2/HIF-1α CODD), Fe(II) (6.3 ± 0.7
μM for PPHD/EF-Tu44–63; <1 μM for PHD2/HIF-1α CODD),
and L-ascorbate (1,064 ± 95 μM for PPHD/EF-Tu44–63; 54 ± 10
μM for PHD2/HIF-1α CODD; SI Appendix, Fig. S4 A–E)
(16–20). Although the results with isolated enzyme may not re-
flect the cellular kinetics, given that PHD2 kinetics are proposed
to reflect its role as a hypoxia sensor, these preliminary differ-
ences are of interest. In particular, the higher Km for Fe(II) is
notable given the phenotypic results on the PPHD insertional
mutant strain, supporting a role for PPHD in iron regulation.
The switch I loop of EF-Tu plays a central role in bacterial
translation by coupling GTP hydrolysis with conformational
changes from the GTP-bound active state to the GDP-bound
inactive state (21, 22). NMR was used to directly monitor
kirromycin-induced GTP hydrolysis by EF-Tuputida; we observed
no difference in the GTP hydrolysis rate for Hyp54 EF-Tu (0.71 ±
0.02 μM/min) and unmodified EF-Tu (0.76 ± 0.08 μM/min;
SI Appendix, Fig. S5A). However, addition of PPHDputida to the EF–
Tu GTP hydrolysis reaction decreased the rate of GTP hydrolysis
in a metal ion and 2OG-dependent manner [Zn(II) 0.60 ± 0.05
μM/min; Zn(II) and 2OG 0.49 ± 0.16 μM/min; Zn(II) was used as
a surrogate for Fe(II) and a PPHDputida inhibitor; SI Appendix,
Fig. S5 B–D]. In P. aeruginosa, we observed no difference in the
global translation rate between the PPHD mutant strain and the
wild-type under standard growth conditions, as measured by
[35S]methionine incorporation (SI Appendix, Fig. S5E). The effect
of PPHDputida on the GTP hydrolysis rate is less with hydroxy-
lated EF-Tu (0.83 ± 0.08 μM/min) (SI Appendix, Fig. S5B), likely
because of the weaker binding of hydroxylated EF-Tu to PPHD.
Using a paramagnetic relaxation enhancement-based NMR
technique [with Mn(II) substituting for Fe(II)], we observed that
addition of EF-Tuprotein decreased the PPHDputida 2OG Kd by
∼50-fold (8 ± 4 μM) compared with the absence of any substrate or
in the presence of EF-Tu44–63 (>400 μM; SI Appendix, Fig. S5F),
implying a substantial interaction interface between PPHDputida and
EF-Tu. These results implied that very substantial interactions be-
tween PPHDputida and EF-Tu likely extend well beyond the im-
mediate active site region. Notably, the observation that PPHDputida
addition decreases the rate of GTP hydrolysis and the location of
Pro54 on the switch I loop suggests that PPHDputida sequesters the
switch I loop. We therefore pursued structural characterization of
PPHDputida, EF-Tu, and the PPHD:EF-Tu complex.
Structure of PPHD. To investigate the structural similarity of
PPHDputida to PHD2, we determined a crystal structure of
PPHDputida complexed with Mn(II) and N-oxalylglycine (NOG),
which are inert substitutes for Fe(II) and 2OG, respectively
(2.0-Å resolution; space group P1). Similar to other 2OG oxy-
genases, PPHDputida contains a double-stranded β-helix (DSBH)
core fold comprising eight β-strands (I–VIII) folded into major
and minor β-sheets that enclose the metal-/2OG-binding sites
(Fig. 2A) (23, 24). Five antiparallel β-strands [β1-β2(I)-β4(III)-β7
(VI)-β9(VIII)] form the major β-sheet, and four antiparallel
β-strands [β3(II)-β5(IV)-β6(V)-β8(VII)] form the minor β-sheet.
Three α-helices (α1–α3) pack against the major β-sheet of the
DSBH. A disordered region (residues 47–71) of PPHDputida
corresponds to the β2–β3 finger loop of PHD2, which is con-
formationally flexible and involved in HIF-α binding (10, 25).
PPHDputida contains a HXD...H triad of metal-binding residues
(His124, Asp126, and His183), which, with the NOG oxalyl
group and a water, complete octahedral metal-coordination.
Although nonidentical, the PPHDputida active site is very similar
to that of PHD2 (10); NOG is positioned between the major and
minor β-sheets of the DSBH such that its C-5 carboxylate forms
a salt bridge with Arg192 (Arg383PHD2) (Fig. 2 B and C). The
clear similarity between PPHDputida and PHD2 supports the
proposal of common ancestry for the two hydroxylases (Fig. 2B).
Structure of a PPHD:EF-Tu Complex. We determined a P. putida
EF-Tu structure (2.3-Å resolution; space group C2). EF-Tuputida
and Escherichia coli EF-Tu have very similar overall folds (rmsd,
1.5 Å over 353 Cα atoms) and Mg(II) binding sites in their inactive
GDP-bound states (Fig. 3A and SI Appendix, Fig. S6 A and B)
(26). The switch I loop of EF-Tuputida (residues 40–62) is disor-
dered; this is notable because the prolyl-hydroxylated regions of
HIF-α are also predicted to be disordered in solution (18).
100
100
0
0
m/z
2230.5
2230.7
2246.6
2230 2238 22462222 2254 2262
I   VEFDKIDSAPEEKARGITI
[O]
A B
R
el
at
iv
e
ab
un
da
nc
e 
(%
)
R
el
at
iv
e
ab
un
da
nc
e 
(%
)
+16 Da
PPHD
EF-Tu
N
X
O
N
X
O
X
X
OH
[O]
PPHD, X=EF-Tu
PHDs, X=HIF
CP4Hs, X=Pro-collagen
44 63
Fig. 1. Identification of EF-Tu as a PPHDputida substrate. (A) PPHDputida,
human HIF (PHDs), and collagen (CP4Hs) prolyl-4-hydroxylases catalyze
4-trans prolyl-hydroxylation. (B) EF-Tu is a PPHDputida substrate; MS spectrum
showing a +16-Da peak revealing PPHDputida-dependent prolyl-4-hydroxyl-
ation of EF-Tu44–63.
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To obtain a structure of a PPHD:EF-Tu protein–protein com-
plex (Fig. 3 A–C), PPHD and EF-Tu were expressed separately to
prevent EF-Tu hydroxylation and then mixed, purified, and
crystallized using Mn(II) and NOG to stabilize and inactivate/in-
hibit PPHD, and Mg(II) and GDP to stabilize EF-Tu. In the re-
sultant PPHD:EF-Tu complex structure (2.7-Å resolution; P31 2 1),
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Fig. 2. PPHDputida is structurally similar to human PHD2. (A) Ribbons representation of the overall structure of PPHDputida; DSBH-associated β-strands (pale cyan),
roman numerals indicate strands in the DSBH, DSBH-extension β-strands (dark blue), α-helices (red), loops (white), NOG (yellow), Mn(II) (pink sphere). (B) Su-
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Fig. 3. A PPHD:EF-Tu complex structure reveals major conformational changes in both proteins. (A) View from a PPHDputida (magenta):EF-Tu (cyan) complex
crystal structure reveals EF-Tu in its GDP-bound state; the EF-Tu switch I loop is located in the PPHD active site positioning Pro54 in its endo-conformation for
trans-4-hydroxylation. Six residues (43–48) in the switch I loop are disordered (dotted line). (Inset) details of how PPHD interacts with EF-Tu domain II. (B) The
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PPHDputida (magenta):EF-Tu (cyan) complex revealing enclosure of the PPHDputida β2–β3 finger loop and the β5(II)–β6(III) thumb loop around the EF-Tu switch
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E. coli EF-Tu, red). (F) Superimposition of the β5(II)–β6(III) thumb loop as in isolated PPHD (green) and in the PPHDputida (magenta):EF-Tu (cyan) complex reveals
reorganization of thumb residues on substrate binding: Phe128PPHD rotates 90° to position its phenyl ring directly behind Pro54EF-Tu; Asp131PPHD forms a salt
bridge with Arg133PPHD; Asp132PPHD rotates 180° to salt bridge to Arg234EF-Tu of EF-Tu domain II, allowing Arg134PPHD to hydrogen bond to Pro54EF-Tu.
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EF-Tu is in its translationally inactive GDP-bound conformational
state consistent with the observed PPHD-mediated inhibition of
GTP hydrolysis. PPHDputida binds EF-Tu between domain I and
domains II/III, occupying a position similar to that observed for EF-
Tu domain I in its GTP-bound active state relative to EF-Tu
domains II/III (Fig. 3D) (27). A Mg(II) ion is present in the EF-Tu
nucleotide binding site, as in the EF-Tu structure without
PPHDputida. Mn(II) and NOG are present in the PPHDputida
active site.
In contrast to the isolated EF-Tuputida structure, in the com-
plex, most EF-Tu switch I loop residues are ordered (16 residues
disordered in isolated EF-Tu; 6 in the PPHD:EF-Tu complex).
In a structure of isolated E. coli EF-Tu (in its inactive GDP-
bound state), all of the switch I loop residues are ordered and
located on the surface of EF-Tu domain I, adopting a loop-helix-
loop-strand conformation (Fig. 3E) (26). Comparison of the
P. putida PPHD:EF-Tu complex crystal structure with that of
E. coli EF-Tu (78% identity; rmsd, 1.2 Å over 338 Cα atoms)
reveals major differences. Relative to the isolated E. coli EF-Tu
structure, in the PPHD:EF-Tu complex structure, the entire
EF-Tu switch I loop pivots around residues Gly41EF-Tu and
Ile61EF-Tu, such that Pro54EF-Tu moves 22 Å and is positioned at
the apex of an extended loop projecting into the PPHDputida
active site (Fig. 3E).
In contrast to the isolated PPHDputida structure, in the
PPHD:EF-Tu complex, the PPHDputida β2–β3 finger loop (resi-
dues 51–74) is ordered and encloses the EF-Tu switch I loop
within the active site (Fig. 3C). The residues at the apex of the
flexible β2–β3 finger loop of PPHDputida adopt a 310-helix con-
formation (residues 58–60). An arginine (Arg57) before the 310-
helix is positioned to form a salt bridge with Asp130 of the
β5(II)-β6(III) “thumb” loop (seven residues, 127–133), forming
a tunnel through which the EF-Tu switch I loop is threaded (Fig.
3C). The β5(II)–β6(III) thumb loop of PPHDputida contains three
arginines, three aspartates (including Asp130), and one phenyl-
alanine, the backbone and side chains of which make interactions
with domain II of EF-Tu and undergo clear conformational
changes relative to their positions in the isolated PPHDputida
structure (rmsd, 1.4 Å; Fig. 3F and SI Appendix, Fig. S6C).
As indicated by the kinetic analyses in solution, the PPHD:EF-Tu
structure reveals substantial enzyme-substrate contacts beyond
the active site. PPHD and EF-Tu share a total interaction in-
terface of 1,662 Å2 (24 hydrogen bonds; 10 salt bridges),
resulting in a calculated ΔGbinding of ∼-9.7 kcal/mol, of which
only 965 Å2 (13 hydrogen bonds; 3 salt bridges) is accounted for
by direct interactions of PPHDputida with the EF-Tu switch
I loop. Other interactions include positioning the PPHDputida
α3-helix into a hydrophobic pocket in the β-barrel of EF-Tu
domain II formed by Phe222EF-Tu, Ile224EF-Tu, and Val230EF-Tu,
and burying Phe265EF-Tu in a hydrophobic pocket formed by the
side chains of Leu101PPHD, Leu103PPHD, and Leu177PPHD (Fig.
3A, Inset). These interactions collectively order the PPHDputida
thumb loop, suggesting that analogous interactions between
PHD2 and full-length HIFα, not observed in a PHD2:HIF-α
fragment structure (25), may occur.
Conservation of Substrate Binding by Prolyl-Hydroxylases. The
positions of the β2–β3 finger loop residues in the complex are
strikingly similar to those observed for PHD2 in complex with
HIF-α and to a collagen prolyl-4-hydroxylase-related protein in
Chlamydomonas reinhardtii (CrP4H) when complexed with a
proline-rich substrate (Fig. 4 A and B and SI Appendix, Fig. S6 D
and E) (25, 28). In PHD2 and CrP4H, the β2–β3 finger loop
(PHD2: 23 residues, 236–258; CrP4H: 24 residues, 76–99) and β5
(II)–β6(III) thumb loop (PHD2: 6 residues; 316–321; CrP4H: 15
residues, 146–160) are of similar length and in the same locations
as those of PPHDputida (Fig. 4 A and B and SI Appendix, Fig. S7 A
and B); however, an analogous Arg57:Asp130 salt bridge that
connects the finger and thumb loops is not present in PHD2
or CrP4H.
The PHD2 C-terminal α-helix is involved in substrate binding
and catalysis (16, 25). The PPHDputida C-terminal loop (residues
201–207, corresponding to PHD2 392–408) directly interacts with
EF-Tu, as does the PHD2 C-terminal α-helix with HIF-α CODD
(Fig. 4A, Inset), suggesting evolutionary conservation of a role for
the C terminus in substrate recognition.
Comparison of the substrate complexes reveals that conserva-
tion is not limited to the enzymes but extends to the bound sub-
strates. Strikingly, the unrelated substrates all adopt closely related
conformations in their active site regions when bound to their
respective prolyl-hydroxylase partners; EF-Tu (residues 50–57)
complexed with PPHD shares a similar orientation and confor-
mation to that of HIF-α (residues 560–567) complexed with PHD2
(backbone atoms rmsd, 0.1 Å) and to that of a proline-rich peptide
complexed with CrP4H (backbone atoms rmsd, 0.1 Å; Fig. 4 A and
B and SI Appendix, Fig. S6 D and E). However, there are differ-
ences in observed substrate binding for the prolyl-4-hydroxylases
(PPHD, PHDs, CP4Hs) and that predicted for prolyl-3-hydrox-
ylases (OGFOD1/Tpa1; SI Appendix, Fig. S7 A and B). The prolyl-
4-hydroxylases have a conserved arginine at their active site
opening positioned to hydrogen bond to the carbonyl of the sub-
strate proline (Arg134PPHD, Arg322PHD2, Arg161CrP4H). Prolyl-
4-hydroxylases also have a conserved tyrosine (Tyr121PPHD,
Tyr310PHD2, Tyr140CrP4H), the hydroxyl of which points toward the
nitrogen of the substrate proline (Fig. 4 A and B and SI Appendix,
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Fig. 4. Pseudomonas PPHD, human PHD2, and C. reinhardtii P4H (CrP4H)
share a conserved mechanism for substrate binding. Overall and active site
superimpositions of the PPHDputida (magenta):EF-Tu (cyan) complex and
both (A) human PHD2 (sand) in complex with HIF-α CODD (residues 556–574;
PDB ID: 3HQR) (green) and (B) CrP4H (green) in complex with proline-rich
peptide substrate (PDB ID: 3GZE) (yellow) reveal conservation of the roles of
the β2–β3 finger loop and the β5(II)–β6(III) thumb loop, the orientation of the
substrate backbone in the active site, and other key substrate binding
interactions. Note that although CrP4H does not share a structurally con-
served Arg133PPHD with PPHD, as does PHD2 (Inset), CrP4H does share
a conserved Glu109PPHD (Glu127CrP4H, Thr296PHD2). (Inset) The PPHDputida and
PHD2 C termini interact differently with their substrates. In contrast, the
PHD2 C terminus interacts directly with HIF-α CODD (25).
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Fig. S6 D and E and S7B). In contrast, the prolyl-3-hydroxylases
have a smaller hydrophobic leucine at the equivalent position to
Tyr121PPHD (Leu156Tpa1, Leu152OGFOD1) (29), which may promote
prolyl-3-hydroxylation over prolyl-4-hydroxylation by adjusting the
position of the proline within the active site.
In the PPHDputida active site, the pyrrolidine ring of Pro54EF-Tu
is observed in a C-4 endo conformation, poised for hydroxylation,
as observed in the PHD2:HIF-α and CrP4H:proline-rich peptide
complexes (Fig. 4 A and B and SI Appendix, Fig. S6 D and E) (25,
28, 30), and in contrast to the C-4 exo conformation, as observed
for prolyl-hydroxylated HIF-1α when complexed with pVHL (1).
Discussion
The combined results suggest that roles for prolyl-hydroxylation
are ancient, extending from EF-Tu in bacteria to, at least, colla-
gen, HIF-α, and ribosomal protein 23 in eukaryotes. The results
support growing evidence for the importance of 2OG oxygenases,
including PHD homologs, in the regulation of translation, as well
as of transcription (5–8, 29, 31–35). It is notable that the Jumonji
C subfamily 2OG oxygenases also play roles in both histone/
chromatin and ribosomal protein modification (5, 36).
Structurally guided bioinformatic analyses are informative with
regard to the distribution of prolyl-hydroxylases. Comparison of
the topologies of the prolyl-3-hydroxylases and prolyl-4-hydrox-
ylases for which crystal structures are available reveals conserva-
tion not only of the DSBH, Fe(II), and 2OG binding sites but also
of other functionally important elements including the β2–β3 finger
loop and α-helices that pack against the DSBH (SI Appendix, Fig.
S7 A and B), enabling assignment of putative prolyl-hydroxylases
with a high confidence level. All identified subtypes of prolyl-4-
hydroxylases (CP4Hs and PHDs) and prolyl-3-hydroxylases
[Leprecans (mammalian collagen prolyl-3-hydroxylases) and
OGFOD1s] are ubiquitous in animals, and all but the Leprecans are
present in choanoflagellates. However, their presence in prokar-
yotes is sporadic, and they are apparently absent in archaea (Fig. 5
and SI Appendix, Fig. S8).
Given that HIF and collagen exist in animals, but not bacteria,
protein prolyl-hydroxylases (and other enzymes catalyzing post-
translational modifications) may have first evolved to catalyze ox-
idation of highly abundant proteins, such as the switch I loop of
EF-Tu, which are part of the translational machinery. Such protein
hydroxylases were possibly derived from 2OG oxygenases acting
on small molecules (e.g., proline-hydroxylases) (37), some of which
have simpler structures than the protein-hydroxylases (23). In
eukaryotes, the prolyl-hydroxylases evolved divergently to catalyze
hydroxylation of collagen and other proteins involved in trans-
lational and transcriptional regulation [e.g., Skp1 and ribosomal
protein 23 (6–9)]. Their role in HIF-α hydroxylation evolved in
animals, possibly via fusion of a basic helix–loop–helix domain
transcription factor with an EF-Tu, collagen, or Skp1-related or
Skp1-derived substrate. The observation that PHD2 interacts with,
but apparently does not hydroxylate, eEF2, the eukaryotic coun-
terpart to prokaryotic EF-G, an EF-Tu homolog (15), is interesting
because it may reflect an ancestral relationship between PPHD and
EF-Tu. Competition between HIF-α and eEF2 [and potentially
other PHD substrates; e.g., pyruvate kinase M2 (38) or centrosomal
protein 192 (39)], may help regulate the hypoxic response in higher
animals. Analogous competition is proposed for factor-inhibiting
HIF (FIH) catalyzed HIF-1α asparagine hydroxylation, which
reduces HIF activity by blocking its interaction with coactivator
proteins (1). Factor-inhibiting HIF also takes ankyrin repeat
domains as substrates in a manner proposed to enable a robust
and tuneable hypoxic response (40).
The conformational changes observed on substrate binding in the
PPHD:EF-Tu complex reveal that major induced fit during 2OG
oxygenase catalyzed protein-modification can occur. The observed
changes will be useful in designing new types of 2OG oxygenase
inhibitors based on various conformational states, rather than active
site iron chelators, which make up most reported 2OG oxygenase
inhibitors, including PHD inhibitors, in clinical trials (41).
The finding that PPHD regulates the production of pyocyanin
implies that iron regulation in P. aeruginosa may be important in
terms of clinically relevant infections. The role of the PHDs in the
hypoxic response has been highlighted in part because of medic-
inal opportunities relating to the treatment of ischemic and re-
lated diseases such as anemia (41). Although regulation of animal
PHD activity by iron availability is well-established [cobaltous ion
induced erythropoiesis is proposed to be via PHD inhibition (41)],
it has had less prominence. P. aeruginosa infections, which often
occur in hypoxic niches, such as in the cystic fibrosis lung (42), can
induce a HIF-mediated hypoxic response in eukaryotic cells by
production of small molecule factors, which have been proposed
to be cyanide (43). Pyocyanin induces HIF-α up-regulation in
human cells (13), likely via PHD inhibition, at least in part by iron
sequestration. Thus, it seems that during some infections, prolyl-
hydroxylases in both human and bacterial cells may be involved in
“cross-talk” involving regulation limited not only by oxygen
availability but also by that of iron and, possibly, 2OG (or other
tricarboxylic acid cycle intermediate or related compounds) (44).
Therefore, the biological roles of the PHDs and PPHDs likely
extend beyond hypoxic sensing in an isolated organism.
From a clinical perspective, the work is relevant to ongoing
trials involving PHD inhibitors for anemia treatment (41). At
least some PHD inhibitors inhibit other 2OG oxygenases (41,
45). There is also increasing use of metal chelators, including
orally active compounds (which inhibit the PHDs by iron che-
lation) (46), for iron overload diseases. Although our work does
not predict what effect, if any, application of clinically applied
PHD inhibitors/iron chelators will have on the course of infec-
tions by bacteria containing PHD homologs, the potential for
effects of PHD inhibitors on infection should be considered.
Materials and Methods
Protein Purification and Crystallization. Recombinant PPHDputida and EF-Tuputida
were produced in E. coli and purified using Ni-affinity and size-exclusion
chromatography. For purification of the PPHD:EF-Tu complex, cell pellets con-
taining either PPHDputida or EF-Tuputida were colysed with Mn(II) and NOG to
prevent EF-Tu hydroxylation and were purified in the same way. For details of
crystallization conditions, data collection and processing, and refinement sta-
tistics, see SI Appendix, SI Materials and Methods, and Tables S1 and S2.
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Fig. 5. Distribution of prolyl-hydroxylases in kingdoms of life. Tracking
putative homologs of the CP4Hs, PHDs, Leprecans (CP3Hs), and OGFOD1s in
representative organisms throughout the kingdoms of life (for phylogenetic
analyses encompassing a wider distribution, see SI Appendix, Fig. S8). CP4Hs
and PHDs catalyze prolyl-4-hydroxylation. Human OGFOD1 catalyzes a single
prolyl-3-hydroxylation, whereas its yeast homolog Tpa1 catalyzes a double
prolyl-3- and prolyl-4-hydroxylation (7).
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P. aeruginosa Phenotypic Analyses. P. aeruginosa PAO1 wild-type and PPHD
insertional knockout mutant strain were grown (28 °C) in various concentrations
of 2,2-bipyridine (0, 1, 5, and 25 mM); the optical density (600 nm, OD600)
was assayed every 60 min. For pyocyanin quantification, 5-mL cultures of
P. aeruginosa wild-type and PA0310 mutant strains grown to stationary
phase were extracted with 3 mL CHCl3 and then back-extracted with 1 mL
0.2 HCl, and then the aqueous phase was decanted and its absorbance
measured at 520 nm. For global translation rate assays, 1-mL cultures of
P. aeruginosa wild-type and PA0310 mutant strains were grown to log
phase (OD600 = 0.5), and the rate of incorporation of [
35S]methionine
(10 μCi/mL) was measured by scintillation counting.
Determination of EF-Tu as a PPHD Substrate.Hydroxylation assays for PPHDputida
contained 10 μM PPHD, 100 μM EF-Tu44–63 (H2N-IVEFDKIDSAPEEKARGITI-
CONH2), 50 μM Fe(II) [prepared from (NH4)2Fe(SO4)2], 2 mM 2OG, 4 mM so-
dium L-ascorbate in 50 mM Hepes at pH 7.5, 500 mM NaCl, and 5% (vol/vol)
glycerol and were quantified by MALDI MS. MALDI MS/MS was performed to
determine the site of hydroxylation. To determine the stereochemistry of hy-
droxylation, acid hydrolyzed of Hyp54-modified EF-Tu44–63 was derivatized and
compared with the elution times of hydroxyproline standards. To analyze EF-Tu
Pro54 hydroxylation, cells were lysed and analyzed by SDS-PAGE, and the EF-
Tu-containing band was excised and subjected to proteosomal digestion (ArgC)
and liquid chromatography-MS/MS. For purification of recombinant Hyp54
EF-Tu, PPHDputida, Fe(II), 2OG, and sodium L-ascorbic acid were added to
the cell lysate at a final concentration of 1 mg/mL, 50 μM, 2 mM, and 4 mM,
respectively, and incubated for 1 h at room temperature. The hydroxylation
status of Pro54 was then analyzed by trypsinolysis and MSMS analysis.
NMR Experiments. Measurements of Mn(II) and 2OG Kd to PPHDputida used
a Bruker AVII 500 instrument. Mixture (160 μL) contained 50 μM apo (i.e.
no metal) PPHDputida, 50 μM MnCl2, 50 μM EF-Tu (full length or EF-Tu44–63 oli-
gopeptide if required), 10 mM MgCl2 and 200 mM NaCl (buffer: ~30 mM Tris-
D11/~20 mM HEPES pH 7.5 in 36.25% H2O and 63.75% D2O) (SI Appendix, Fig.
S6 F and G). For EF-Tu GTP-GDP turnover assays, we used a Bruker AVIII 700
instrument/5-mm inverse cryoprobe. Incubations (160 μL) contained 10 μM un-
modified or Hyp54 EF-Tu, 50 μM kirromycin, 100 μM GTP, 50 μM apo-PPHDputida
(if required), 100 μM ZnCl2 (if required), 100 μM 2OG (if required), 10 mM
MgCl2, and 200 mM NaCl [buffer: 50 mM HEPES (pH 7.5) in 90% H2O/10%
D2O]. Solutions were buffered using ∼30 mM Tris-d11 and ∼20 mM Hepes at
pH 7.5 in 36.25% H2O and 63.75% D2O]. For ZnCl2 inhibition experiments,
the mixture contained 10 μM apo PPHDputida, 50 μM FeCl2, 500 μM 2OG, 600
μM EF-Tu44–63, 400 μM ZnCl2 (if required), 1.25 mM ascorbate, and 100 mM
NaCl buffered using 50 mM Tris-D11 at pH 7.5 (SI Appendix, Fig. S5D).
See SI Appendix, SI Materials and Methods.
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